title: Sensitivity of transplantable melanoma cells to cytokines with regard to their spontaneous apoptosis.
abstract: OBJECTIVE
  Changes in the sensitivity of two lines of transplantable melanoma cells to the antiproliferative activity of interleukin 6 (IL-6), oncostatin M (OSM), tumor necrosis factor-alpha (TNF-alpha) during melanoma progression were the subject of this study. We were looking for a correlation between these changes and the ability of melanoma cells to undergo spontaneous apoptosis.
  
  
  METHODS
  The influence of exogenous cytokines on the proliferation of melanoma cells was measured by colorimetric methods with MTT and apoptosis of these cells was estimated by staining with annexin V/propidium iodide, measurement of DNA degradation and cell cycle analysis.
  
  
  RESULTS
  It was observed that during melanoma progression the sensitivity of those two melanoma line cells to the antiproliferative effect of IL-6 and OSM did not change, while a spontaneous alteration of the melanotic line into an amelanotic one seemed to be accompanied by resistance of the amelanotic melanoma cells to the antiproliferative activity of TNF-alpha. Simultaneously, we observed a decreased ability of amelanotic melanoma cells (in comparison with the native line) to undergo spontaneous apoptosis.
  
  
  CONCLUSIONS
  The observed resistance to the TNF-alpha antiproliferative effect which appears during melanoma progression seems to be correlated with a lower ability of the amelanotic melanoma cells to undergo spontaneous apoptosis.
authors.affiliation: Department of Embryology, Medical University of Gdańsk, Poland. ceclia@amedec.amg.gda.pl
authors.forename: K
authors.initials: K
authors.lastname: Kozłowska
authors.forename: M
authors.initials: M
authors.lastname: Zarzeczna
authors.forename: M
authors.initials: M
authors.lastname: Cichorek
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects*; D002455:Cell Division / Q000187:drug effects; D006224:Cricetinae; D016207:Cytokines / Q000494:pharmacology*; D053938:DNA Fragmentation / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D005434:Flow Cytometry; D015850:Interleukin-6 / Q000494:pharmacology; D008297:Male; D008545:Melanoma / Q000378:metabolism / Q000473:pathology*; D018328:Melanoma, Amelanotic / Q000378:metabolism / Q000473:pathology*; D009368:Neoplasm Transplantation; D053683:Oncostatin M; D010455:Peptides / Q000494:pharmacology; D012878:Skin Neoplasms / Q000378:metabolism / Q000473:pathology*; D013778:Tetrazolium Salts / Q000378:metabolism; D013844:Thiazoles / Q000378:metabolism; D014407:Tumor Cells, Cultured / Q000187:drug effects; D014409:Tumor Necrosis Factor-alpha / Q000494:pharmacology
chemical_list: D000970:Antineoplastic Agents; D016207:Cytokines; D015850:Interleukin-6; D010455:Peptides; D013778:Tetrazolium Salts; D013844:Thiazoles; D014409:Tumor Necrosis Factor-alpha; D053683:Oncostatin M; C022616:thiazolyl blue